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PURPOSE: To determine the variability of lesion size measurements in computed tomography data sets of patients
imaged under a “no change” (“coffee break”) condition and to determine the impact of two reading paradigms on
measurement variability. METHOD AND MATERIALS: Using data sets from 32 non-small cell lung cancer patients
scanned twice within 15 minutes (“no change”), measurements were performed by five radiologists in two
phases: (1) independent reading of each computed tomography dataset (timepoint): (2) a locked, sequential
reading of datasets. Readers performed measurements using several sizing methods, including one-dimensional
(1D) longest in-slice dimension and 3D semi-automated segmented volume. Change in size was estimated by
comparing measurements performed on both timepoints for the same lesion, for each reader and each
measurement method. For each reading paradigm, results were pooled across lesions, across readers, and across
both readers and lesions, for each measurement method. RESULTS: The mean percent difference (±SD) when
pooled across both readers and lesions for 1D and 3D measurements extracted from contours was 2.8 ± 22.2%
and 23.4 ± 105.0%, respectively, for the independent reads. For the locked, sequential reads, the mean percent
differences (±SD) reduced to 2.52 ± 14.2% and 7.4 ± 44.2% for the 1D and 3D measurements, respectively.
CONCLUSION: Even under a “no change” condition between scans, there is variation in lesion size measurements
due to repeat scans and variations in reader, lesion, and measurement method. This variation is reduced when
using a locked, sequential reading paradigm compared to an independent reading paradigm.
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Advances in computed tomography (CT) technology over the past
several decades have led to exquisitely detailed descriptions of anatomy
and pathology and rapidly decreasing doses. The current multidetector
row CT systems permit the acquisition of submillimeter thickness
image data sets of a patient’s entire thorax in a single breath hold. These
very highresolution image data sets can also be used with advanced
three-dimensional (3D) techniques to visualize and quantify anatomy
and pathology with unprecedented detail and accuracy, using relatively
noninvasive techniques. This has led to lesion size measurements
derived from CT images being heavily used in the assessment of
treatment response in the setting of cancer patients.
Despite advances in both CT technology and our understanding of
cancer’s cellular and molecular mechanisms, the current standard
method to measure tumor response to therapy using CT remains the
Response Evaluation Criteria in Solid Tumors (RECIST), which
is based on unidimensional, linear measurements of tumor diameter
[1–3]. Because it is based on a series of linear measurements, RECIST
offers a simple approach that requires minimal effort. The RECIST
guidelines, however, presume that tumors are spherical and change in
a uniform manner. Significant variability in the RECIST measure-
ments exists across different observers [4], and published work
generally focuses on the surrogate of “best overall response,” with only
a few methods addressing other imaging endpoints such as “time to
progression” and “disease-free survival.” As a therapy response
measurement procedure, RECIST maps these linear measurements
into one of four categories: complete response, partial response, stable
disease, and progressive disease.
Because it uses only unidimensional linear measurements in its
assessment, the RECIST criteria do not fully use the much higher
resolution data sets offered by modern multidetector row CT systems.
This may limit the ability to accurately reflect size changes that occur
in the many lesions that are not spherical in nature and may
ultimately limit the ability to identify early changes in patients
undergoing treatment [4,5]. The advances in CT technology
described above had led to the development of 3D methods to
estimate the volume of lung lesions, with the aim of developing more
accurate and consistent measurements, even for non-spherical lesions,
to ultimately better assess response over a shorter time interval.
Tumor volumetric measurements may be more sensitive indicators of
change and, by inference, response to treatment. However, volume
measurements are fundamental estimates that have variability from
multiple sources—patient effects, scanner-related effects, measure-
ment and reader effects, and so on. Petrick et al. [6] investigated the
use of anthropomorphic phantoms to estimate and compare the bias
and variance of measurements of the size of spherical and complex
simulated lung nodules using unidimensional, bidimensional, and
volumetric measures. They showed that 3D volumetric measure-
ments in phantom lesions demonstrate a smaller bias as well as smaller
variability compared to unidimensional measurements, especially for
complex lesion shapes.
This effort extends the previous work related to the use of several
sizing methods from CT image data as a biomarker of response by
reporting on investigations that used “coffee break” CT data sets
where patients were scanned twice within a very short (15-minute)
period of time using the same imaging technique and on the same
scanner [7,8]. These data sets were then analyzed with several size
measurements (including unidimensional, bidimensional, and volu-
metric methods) to assess measurement variability under a “nochange” condition. Measurements were performed by five different
radiologists under two different reader paradigms described below and
allow us to estimate the inherent variability in measuring lesions in
patient data sets using several different size measures. These estimates
of variability will in turn inform thresholds for determining whether a
meaningful change has occurred in tumor size.
The purpose of this work was to quantify the variability of lesion
size measurements under a “no change” condition with an
independent radiology reading facility performing reads under two
distinct reading conditions. The reading was performed under one
condition where reads were done independently and one where reads
were done with a locked, sequential reading paradigm, which is more
reflective of clinical trials practice.
Methods
This study was carried out in two phases, which were defined in terms
of the reading paradigm used in each phase. In the first phase
(“independent read”), radiologists read each time point of each case
independently in random order, and they were not allowed to consult
any previous measurements they made on the case. In the second
phase (“locked sequential read”), radiologists read the first time point
scan, locked their measurements, and then made measurements on
the second time point scan while being allowed to review their prior
measurements on the first time point scan.
Case Selection and Inclusion Criteria
The first phase of this study used the “no change” cases from the
publicly available Reference Image Database to Evaluate Response to
Therapy (RIDER) database [9] that were originally performed at the
Memorial Sloan Kettering Cancer Center [7,8]. This data set
consisted of 32 non-small cell lung cancer patients who were scanned
twice on the same scanner within 15 minutes. Each data set consisted
of a thoracic CT scan performed without the use of any iodinated
contrast agent and reconstructed with thin section (1.25 mm) images.
For these data sets, only one lesion per patient was selected for
measurement (32 lesions total), with each lesion visible on each of
the two time point (time point 1 and time point 2) scans. The
approximate lesion diameters ranged from 8 to 40 mm. The shapes of
the selected lesions ranged from simple and isolated to complex and
cavitated. A few sample lesions are illustrated in Figure 1.
For the second phase of this study, a set of distractor lesions was
identified from the RIDER data set. The purpose of these distractor
lesions was to reduce bias in the reader study by having radiologists
also measure lesions that change. These distractor cases would reduce
the potential for readers to recognize or assume that every case they
were measuring was a “no change” case. Therefore, these cases were
not from the “coffee break” data set but were selected from other RIDER
databases containing thoracic CT scans of non-small cell lung cancer
patients performed without the use of any iodinated contrast agent.
Twenty lesions were selected from patients who had multiple scans
(even if they were months apart), who were reconstructed with thin
sections (≤1.25 mm thickness), and who demonstrate some amount of
change in the CT-based lesion size across the two selected scans.
In this study, only the coffee break lesions were analyzed; the distractor
change cases served only to control potential reader bias. The analysis cases
were retrospectively divided into two types as follows: 1) lesions that were
classified as meeting the conditions described in the “Claims” section of
the “Quantitative Imaging Biomarker Alliance (QIBA) Profile: CT
Tumor Volume Change (CTV-1)” [10] and 2) lesions that did not meet
Figure 1. Examples of lesions used: (A) and (B) are examples of lesions that were judged to have met the QIBA CTV-1 profile claim [10],
while (C) and (D) are examples of lesions that were judged to have not met the QIBA CTV-1 profile claim.
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profile states that the claims are only applicable “when the given tumor is
measurable (i.e. tumor margins are sufficiently conspicuous and
geometrically simple enough to be recognized on all images….) and
the longest in-plane diameter of the tumor is 10 mm or greater.”
Therefore, lesions described as meeting the QIBA CTV-1 profile were
those that were judged to have clearly identified tumor margins by one of
the authors (M.F.M.-G.) who was also part of the QIBA profile
development team; all coffee break lesions used in this study exceeded the
10-mm diameter threshold.
Readers
For phase 1, five readers performed the measurements described
below. The number of readers was based on recommendations
[11,12] and available resources. For phase 2, there were also five
readers, three of whom participated in phase 1. All readers were
board-certified radiologists with experience as readers for multicenter
oncology clinical trials. All were experienced with performing linear
measurements as part of the RECIST assessment protocol.
Reading Software
The cases were reviewed and the lesion size measurements were made
using amodified software package that the readers were familiar with from
oncology readings performed as part of their normal workload. Therefore,
all readers could use the software to load, view, and measure lesions for
single longest diameter measurements and bidirectional diameter
measurements. For volumetric measurements, readers were trained on
the modified software that allowed them to create and edit contours of
each lesion. From the contours, lesion volumewas calculated. In addition,
the single longest diameter and bidirectional diameters were derived from
the lesion contours.
Measurements
In phase 1 of the study, each radiologist measured each lesion in three
different ways as described below. For this phase, each measurement was
made independently in a separate reading session, so the reader did not
have access to any of their prior measurements for reference:
• 1D: manual linear measurements using a Caliper tool to obtain the single
longest diameter on one image.
• 2D:manualbidirectional diameters using theOrthogonalRuler tool toobtain the longest
diameter and diameter perpendicular to the longest diameter. Because this measurement
was done independently, the single longest diameter was also retained for comparison.
• 3D: algorithm assisted volume using the boundary contour tool. These volumetric
measurementsweremade using software based on aprototype proprietary semiautomated
tool (Oncocare Prototype; SiemensCorporateResearch, Princeton,NJ),which included a
lesion segmentation component [13,14]. The 3D measurement process was given asfollows: the reader 1) defined a seed stroke across the lesion (i.e., a RECIST-like line across
the perceived maximum diameter of the lesion), 2) applied the segmentation tools,
3) evaluated the quality of the segmentation, and 4) refined or added seed strokes and
reapplied the segmentation tool until satisfiedwith the3Dnodule segmentation.Fromthe
resulting contour, the volumewas calculated aswell as both the single longest diameter in a
given image and the diameter perpendicular to that longest diameter.
In phase 2, using the same boundary contour tool described above, the
readers were asked to obtain the entire lesion boundary contour for both
the no change lesions and the distractor lesions. From each contour,
the 3D volume values were obtained; in addition, the 1D single longest
diameter and 2D longest and perpendicular diameter values were
automatically derived from the same contour information.
Reading Experiments
As mentioned above, the reading experiments were carried out in
two distinct phases.
Phase 1— Independent readings. In this phase, readers were shown only the original 32 “no
change” lesions described above.The lesion identified in each time point scanwas
assessed in a different session. Readers were not allowed to see any of their
previousmeasurements (to ensure that eachmeasurement was done independently).
Measurements were performed using the three methods described above, but
eachmeasurement typewas performed in a different session.The order of reading
was randomized by patient, scan (time point 1 and time point 2), and
measurement type. Reading order was different for each reader as well.
Phase 2— Locked sequential readings. In comparison to the independent reading paradigm
of phase 1, this phase allowed the readers to perform a “locked, sequential read”
that allow the reader to see the measurements they made on the previous time
point scan. In this phase, due to time (and budget) constraints, the readers only
provided the contours of the entire lesion boundary. From these contours, lesion
volume and longest diameter were estimated. To prevent possible bias in this
reading paradigm associated with the readers recognizing or assuming that all of
the cases were “no change” data sets in this phase, the readers were not told the
aims of the study and were shown both the original 32 “no change” lesions
described above as well as the 20 distractor lesions. It should be noted that only
the measurements performed on the “no change” lesions were used in analysis
and it is assumed their volume change across the two time points was zero.
The locked, sequential read was accomplished by 1) first showing
the reader one time point scan (randomly selected time point 1 or
time point 2), having the reader contour the entire lesion boundary,
locking that result (i.e., no editing allowed), and then 2) immediately
showing the reader the other time point scan, allowing the reader to
see the contour on the previously measured lesion and then having
the reader contour the entire lesion on the second scan. No copy/
paste of lesion contours was allowed. In this phase, the order of
reading was randomized only by patient. As in phase 1, the reading
order was different for each reader.
58 Variability of Lesion Size Measurements in CT McNitt-Gray et al. Translational Oncology Vol. 8, No. 1, 2015Analysis
Size estimates from six different size measurements were provided
by each of the five readers in the phase 1 independent reads: 1D
longest diameter from the caliper, from the orthogonal ruler, and
from the contoured lesion, 2D area measurement defined as the
product of the longest and perpendicular diameters from the
orthogonal ruler and the contoured lesion, and a volume estimate
from the contoured lesion. For the second reading phase of locked,
sequential reads, three size measurements were provided by the
second set of five readers: the 1D, 2D, and volume from a contoured
lesion. The percent change between the two time point scans was
calculated as the ratio of the difference in the second read and the first
read to the first read. The proportional change was calculated as the
ratio of the difference between the second read and the first read to
the average between the first and second reads. Descriptive summary
statistics and changes were reported for each phase.
Percent change %ð Þ ¼ a metric in the second scan−a metric in the first scan
a metric in the first scan
 100 1
Proportional change %ð Þ ¼ a metric in the second scan−a metric in the first scan
mean of metrics in the two scans
 100 2
The 95% confidence interval (CI) of the mean and SD were derived
from estimation of 1000 bootstrap replications of the observed data and
were reported with a Bonferroni adjustment for multiple comparisons.
Bland Altman plots [15] were used to show the repeatability in
measurements between two scans by an individual reader. A mixed effect
model [16] was used to test the differences in percent changes between
independent reading and locked sequential read, where a fixed covariate is
a dichotomized QIBA type (a QIBA CTV-1 compliant lesion or a non–
QIBA CTV-1 compliant lesion as described in [10]) and random effects
are subjects and readers nested into a subject.
Box-and-whisker plots are used to show the distribution in the
percent change in volume by a QIBA-compliant group versus a non-
compliant group over the two reading phases. A line within a box
indicates the median. The lower hinge and upper hinge indicates 25th
and 75th percentiles of data (i.e., interquartile range, IQR). The lower
and upper adjacent lines connected to the boxes are 1.5 times of the
range of 75th and 25th percentiles. Likewise, the dots are outside
values either smaller or greater than the 25th percentile − 1.5 times
the IQR or 75th percentile + 1.5 times the IQR, respectively.
A subgroup analysis was also performed with two subgroups: 1) the
20 lesions that were identified as meeting the QIBA CTV-1 profile
language (as described in the Case Selection and Inclusion Criteria
section above) and 2) the 12 lesions that did not meet the QIBATable 1.Mean Value Results (and SD), Differences, and Percent Changes for the Independent Readin
Sizing Method Independent Reading (N = 160 = 32 × 5 Readers)
First Scan Second Scan
Mean ± SD (mm, mm2, mm3) Mean ± SD (mm, mm
1D caliper, mm 33.1 (±19.8) 33.9 (±19.6)
1D orthogonal ruler, mm 32.8 (±20.0) 33.8 (±19.8)
1D from contour, mm 34.2 (±20.1) 34.0 (±19.1)
2D orthogonal ruler, mm2 1009 (±1204) 1060 (±1217)
2D from contour, mm2 1098 (±1393) 1067 (±1272)
3D, 1000mm3 22.14 (±36.2) 22.11 (±35.0)CTV-1 profile language. The results of each subgroup were provided
as well as the pooled results.
In all analyses, a threshold of .05 for a P value was considered to be
significant and a threshold between .05 and .1 was considered to show
a trend.
Results
Table 1 provides the mean size measurement results, the mean change
in size, and the mean percent changes for the independent reading
(phase 1) results. These results are stratified by measurement type and
pooled across readers and lesions. It should be noted that for
consistency in units and to avoid reporting very large numbers, the
volume results in Table 1 are given in units of 1000 mm3. These
results indicate that for the independent reading paradigm, the mean
percent change for 1D measurements is quite low (mean value of
b6%), while the mean percent change for 3D volumetric
measurements can be substantially higher (mean value approximately
25%). This table also shows that the mean and SDs of the 1D results
are not very different between the various methods of obtaining the
longest diameter (direct manual measurement, obtained from
perpendicular diameters or extracted from the volumetric contour).
Finally, the table shows that both percent changes and the SDs were a
bit larger for the 2D methods than those for the 1D methods.
Table 2 provides similar mean size results plus the mean change in
size and mean percent changes for the locked sequential reading
(phase 2) results. These results are similarly stratified by measurement
type and pooled across readers and lesions. These results indicate that
for the locked sequential reading paradigm, the mean percent change
for 1D measurements is even lower than those in Table 1, showing a
mean percent change of only 2.5%. In this reading paradigm, the
mean percent change for 3D volumetric measurements were also
substantially reduced, demonstrating a mean value of only 7.4% and
2D measurements demonstrate a mean percent change of only 2%
(P = .063 and P = .111, retrospectively). The SDs of percent changes
are also much smaller here than in the independent reading paradigm
reported in Table 1.
Subgroup Analyses
Table 3 shows the mean percent change as well as that of the
proportional percent change and the 95% CIs for the independent
phase 1 readings broken down by 1) lesions that were identified as
being compliant with the QIBA CTV-1 profile, 2) lesions that were
identified as not being compliant with the QIBA CTV-1 profile, and
also 3) the pooled results across all lesions. Table 4 shows the SDs of
percent change and proportional percent (and 95% CIs) for the
independent readings (phase 1), also broken down by lesion category
and sizing method. These results indicate that the mean percentg (Phase 1) for Each of the Six Sizing Methods Used. Results Are Pooled across Readers and Lesions
Percent
Changes (%)
Proportional
Changes (%)
Difference
2, mm3) Mean ± SD (mm, mm2, mm3) Mean ± SD Mean ± SD
0.8 (±5.1) 5.8 (±23.8) 3.6 (±19.2)
1.0 (±4.3) 5.4 (±21.2) 3.6 (±16.6)
−0.2 (±5.2) 2.8 (±22.2) 0.9 (±17.6)
51 (±211) 15.2 (±68.5) 6.2 (±29.6)
−31 (±357) 12.7 (±69.0) 2.0 (±35.4)
−0.03 (±7.7) 23.4 (±105) 5.5 (±39.2)
Table 2.Mean Value Results (and SD), Differences, and Percent Changes for the Locked Sequential Reading (Phase 2) for Each of the Three Sizing Methods Used. Results Are Pooled across Readers and
Lesions
Sizing Method Locked Sequential Read (N = 160 = 32 × 5 Readers) Percent
Changes (%)
Proportional
Changes (%)
First Scan Second Scan Difference
Mean ± SD (mm, mm2, mm3) Mean ± SD (mm, mm2, mm3) Mean ± SD (mm, mm2, mm3) Mean ± SD Mean ± SD
1D from contour, mm 34.4 (±20.5) 34.8 (±20.4) 0.4 (±3.6) 2.5 (±14.2) 1.7 (±12.0)
2D from contour, mm2 1156.5 (±1439) 1155.3 (±1454) −1.2 (±307) 2.1 (±21.2) 0.1 (±18.9)
3D, 1000mm3 22.9 (±37.4) 22.8 (±37.3) −0.06 (±5.4) 7.4 (±44.2) 2.2 (±25.5)
Table 3. Estimates of Mean Percent Change and Proportional Change (95% CIs in Brackets) as a Function of Nodule Category and Sizing Method for the Independent Reading (Phase 1).
Phase 1—Independent Read Mean Percent Change
Nodule Category Sizing Method Mean Percent Change (%) †
and 95% CI
Standard Error Mean Proportional Change
(%) † and 95% CI
Standard Error
QIBA profile compliant (N = 100; 20 lesions and five readers) 1D caliper 6.95 [−0.72, 14.61] 2.55 4.28 [−2.11, 10.69] 2.13
1D ruler 7.16 [0.60, 13.71] 2.18 5.26 [0.40, 10.12] 1.62
1D contour 4.92 [−2.24, 12.08] 2.38 2.82 [−2.38, 8.02] 1.73
2D ruler 19.40 [−3.73, 42.54] 7.69 8.55 [0.02, 17.08] 2.83
2D contour 13.48 [−8.90, 35.86] 7.44 3.12 [−6.20, 12.45] 3.10
3D volume 30.31 [−10.13,70.76] 13.45 9.05 [−0.80, 18.86] 3.26
QIBA profile non-compliant (N = 60; 12 lesions and five readers) 1D caliper 3.98 [−3.78, 11.76] 2.54 2.31 [−4.16, 8.76] 2.11
1D ruler 2.54 [−4.80, 9.88] 2.40 0.94 [−5.83, 7.71] 2.21
1D contour −0.88 [−7.94, 6.18] 2.31 −2.41 [−9.38, 4.55] 2.28
2D ruler 8.23 [−8.96, 25.44] 5.62 2.38 [−9.54, 14.30] 3.90
2D contour 11.43 [−12.56, 35.44] 7.84 0.15 [−16.93, 17.23] 5.58
3D volume 16.12 [−16.39, 48.63] 10.62 −0.27 [−19.05, 18.52] 6.14
All (N = 160; 32 lesions and five readers) 1D caliper 5.84 [0.31, 11.36] 1.86 3.55 [−0.95, 8.04] 1.51
1D ruler 5.42 [0.37, 10.47] 1.69 3.64 [−0.24, 7.52] 1.30
1D contour 2.75 [−2.34, 7.83] 1.71 0.86 [−3.22, 4.93] 1.37
2D ruler 15.21 [−0.85, 31.28] 5.39 6.24 [−0.52, 12.99] 2.27
2D contour 12.71 [−3.41, 28.84] 5.41 2.01 [−6.43, 10.44] 2.83
3D volume 23.40 [−2.36, 52.34] 9.18 5.55 [−3.68, 14.78] 3.10
† 95% CIs, based on t-distribution with bootstrap within each subgroup and adjusted using a Bonferroni correction for comparisons of all six types of sizing methods, are shown in brackets.
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types (QIBA CTV-1 compliant or non–QIBA CTV-1 compliant) in
the independent reading paradigm; they are not statistically
significantly different (P = .469 and P = .719, respectively). ThisTable 4. Estimates of SD of the Percent Change and Proportional Change (95% CIs in Brackets) as
Phase 1—Independent Read SD Percent Change
Nodule Category Sizing Method SD of
and 95
QIBA profile compliant (N = 100; 20 lesions and five readers) 1D caliper 25.79
1D ruler 22.02
1D contour 24.17
2D ruler 79.65
2D contour 73.94
3D volume 102.21
QIBA profile non-compliant (N = 60; 12 lesions and five readers) 1D caliper 20.21
1D ruler 19.52
1D contour 18.01
2D ruler 43.63
2D contour 60.52
3D volume 110.02
All (N = 160; 32 lesions and five readers) 1D caliper 23.83
1D ruler 21.17
1D contour 22.18
2D ruler 68.45
2D contour 69.02
3D volume 105.01
† 95% CIs, based on bootstrap t statistic using 1000 replications within each subgroup and adjusted using a
random sampling of the bootstrapping, it is not necessarily expected that the 95% CIs will be symmetric abouappears to be true regardless of the sizing method (1D, 2D, 3D) used.
There are differences between the methods themselves, but these
differences do not change depending on the nodule category. In
addition, these results show that for the independent readinga Function of Nodule Category and Sizing Method for the Independent Reading (Phase 1)
Percent Change (%) †
% CI
Standard Error SD of Proportional Change
(%) † and 95% CI
Standard Error
[11.34, 40.24] 4.92 20.56 [11.91, 29.20] 2.95
[6.99, 37.04] 5.12 16.18 [8.35, 24.02] 2.67
[9.13, 39.21] 5.12 17.46 [9.10, 25.81] 2.85
[1.68, 157.62] 26.56 29.22 [15.19, 43.25] 4.78
[7.76, 140.11] 22.55 31.45 [17.26, 45.65] 4.84
[30.28, 174.13] 39.09 33.11 [15.57, 50.67] 5.98
[8.02, 32.39] 4.15 16.70 [9.07, 24.33] 2.60
[7.13, 31.91] 4.22 17.00 [8.18, 25.83] 3.01
[9.21, 26.81] 3.00 17.56 [9.45, 25.67] 2.76
[3.82, 83.44] 13.56 29.93 [15.90, 43.96] 4.80
[25.44, 95.61] 11.95 41.39 [25.94, 56.84] 5.26
[54.08, 165.96] 19.21 47.76 [28.57, 66.95] 6.54
[13.47, 34.19] 3.53 19.17 [12.89, 25.44] 2.14
[10.37, 31.97] 3.68 16.58 [11.14, 22.01] 1.85
[11.48, 32.88] 3.65 17.62 [11.65, 23.60] 2.04
[11.58, 125.32] 19.37 29.55 [19.12, 39.97] 3.55
[24.73, 113.31] 15.09 35.41 [24.96, 45.86] 3.56
[62.89, 147.30] 14.38 39.37 [28.89, 49.85] 3.57
Bonferroni correction for comparisons of all six types of sizing methods, are shown in brackets. Due to the
t the SD.
Table 5. Estimates of Mean Percent Change and Proportional Change (95% CIs in Brackets) as a Function of Nodule Category and Sizing Method for the Locked, Sequential Reading (Phase 2)
Phase 2—Locked, Sequential Read Mean Percent Change
Nodule Category Sizing Method Mean Percent Change
(%) † and 95% CI
Standard Error Mean Proportional
Change (%) and 95%CI
Standard Error
QIBA profile compliant (N = 100; 20 lesions and five readers) 1D contour 2.42 [−2.41, 7.24] 1.60 1.40 [−2.45, 5.26] 1.28
2D contour 0.66 [−6.01, 7.32] 2.22 −1.35 [−7.39, 4.70] 2.01
3D volume 8.32 [−6.60, 23.23] 4.96 2.09 [−5.49, 9.66] 2.52
QIBA profile non-compliant (N = 60; 12 lesions and five readers) 1D contour 2.69 [−1.77, 7.15] 1.46 2.09 [−1.97, 6.15] 1.33
2D contour 4.40 [−3.53, 12.33] 2.59 2.56 [−4.43, 9.55] 2.29
3D volume 5.92 [−6.07, 17.93] 3.92 2.36 [−7.27, 2.00] 3.15
All (N = 160; 32 lesions and five readers) 1D contour 2.52 [−0.28, 5.33] 1.16 1.66 [−0.68, 4.01] 0.97
2D contour 2.06 [−2.12, 6.24] 1.73 0.12 [−3.41, 3.65] 1.46
3D volume 7.42 [−0.98, 15.82] 3.47 2.19 [−2.52, 6.90] 1.95
† 95% CI, based on t-distribution within each subgroup and adjusted using a Bonferroni correction for comparisons of the three types of sizing methods, are shown in brackets.
Table 6. Estimates of SD of the Percent Change and Proportional Change (95% CIs in Brackets) as a Function of Nodule Category and Sizing Method for the Locked, Sequential Reading (Phase 2)
Phase 2—Locked, Sequential Read SD Percent Change
Nodule Category Sizing Method SD of Percent Change
(%) † and 95% CI
Standard Error SD of Proportional Change
(%) and 95%CI
Standard Error
QIBA profile compliant (N = 100; 20 lesions and five readers 1D contour 15.82 [7.17, 24.46] 2.94 12.89 [6.99, 18.79] 2.01
2D contour 21.90 [10.26, 33.53] 3.96 19.14 [12.56, 25.73] 2.24
3D volume 50.64 [9.07, 92.21] 14.16 26.47 [14.15, 38.79] 4.20
QIBA profile non-compliant (N = 60; 12 lesions and five readers) 1D contour 11.07 [7.00, 15.14] 1.39 10.48 [7.02, 13.94] 1.18
2D contour 19.82 [12.77, 26.87] 2.40 18.45 [13.21, 23.69] 1.79
3D volume 30.95 [10.36, 51.54] 7.02 23.97 [13.25, 34.70] 3.65
All (N = 160; 32 lesions and five readers) 1D contour 14.19 [8.02, 20.35] 2.10 12.01 [8.06, 15.97] 1.35
2D contour 21.16 [13.47, 28.85] 2.62 18.92 [14.52, 23.32] 1.50
3D volume 44.20 [15.43, 72.97] 9.80 25.48 [16.78, 34.19] 2.97
† 95% CI, based on t-distribution within each subgroup and adjusted using a Bonferroni correction for comparisons of the three types of sizing methods, are shown in brackets.
Figure 2. Box plots of volume percent change by lesion category
and reading phase (phase 1—independent reads; phase 2—locked
sequential reads). The dashed lines represent the ±30% change
values described in the QIBA CTV-1 profile.
60 Variability of Lesion Size Measurements in CT McNitt-Gray et al. Translational Oncology Vol. 8, No. 1, 2015paradigm, the mean and SD percent change values are higher for
volume (3D) than for perpendicular diameters (2D), which are higher
than single diameters (1D).
Table 5 shows the mean values of the percent change, the
proportional percent change, as well as 95% CIs for the locked
sequential readings (phase 2) broken down by 1) lesions that were
identified as being compliant with the QIBA CTV-1 profile, 2)
lesions that were identified as not being compliant with the QIBA
CTV-1 profile, and also 3) the pooled results of all lesions. Table 6
shows SDs of percent change and proportional percent (and 95%
CIs) for the locked sequential readings (phase 2), also broken down by
lesion category and sizing method. These results indicate that the
mean percent change and the SD of the percent change are similar
between lesion types (QIBA CTV-1 compliant or non–QIBA CTV-1
compliant) in the locked sequential reading paradigm; they are not
statistically significantly different (P = .739 and P = .940,
respectively). This appears to be true regardless of the sizing method
(1D, 2D, 3D) used. In addition, Table 5 shows that for this locked
sequential reading paradigm, the mean percent change values are now
much more similar between sizing methods and that the proportional
change values are nearly identical across the lesion types for all of the
sizing methods. Table 6 does show that there are still differences in
the SDs between sizing methods, with volume (3D) having a larger
SD than for perpendicular diameters (2D), which are in turn higher
than single diameters (1D).
Figure 2 illustrates the effect of the reading paradigm (independent
reading of phase 1 vs the locked sequential reading in phase 2) on the
percent change for the two categories of lesions identified in this study
(QIBA CTV-1 compliant vs non–QIBA CTV-1 compliant). Thisfigure shows that in phase 1, the median (interquartile range) in
percentage changes is 0.7% (18.6%) for QIBA CTV-1 compliant
lesions and 2.8% (32.9%) for the non-compliant type. In phase 2,
median (interquartile range) in percentage changes are −0.8%
(20.9%) for the QIBA CTV-1 compliant type and 2.7% (16.3%)
for the non-compliant type.
For lesions that would not be considered to be compliant with the
QIBA CTV-1 profile, the interquartile range has been reduced in half
Figure 3. Bland-Altman plots of volume percent change by reading phase (phase 1—independent reads; phase 2—locked sequential
reads) for individual readers, plotted as a function of lesion volume (in 1000 mm3). The dashed lines represent 1 SD from the mean. It
should be noted that the readers in phase 1were not the same five readers as in phase 2 (hence, readers are identified by number in phase
1 and by letter in phase 2).
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compared with an independent reading paradigm (phase 1). Within
these QIBA non-compliant lesions, a trend toward reducing the
percent error was found between phases by the mixed effect model,
but this difference was not statistically significant (P = .069). Within
the QIBA CTV-1 compliant data set, there was no statistically
significant difference in going from independent reading to the locked
sequential reading based on percent error (P = .363).
This figure also demonstrates that for the QIBA CTV-1 compliant
lesions, the percentage of observations in which the volume percent
change falls within ±30% (as stated in the QIBA CTV-1 profile claim
language) is 84.0% (84 of 100 observations − 20 lesions × 5 reviewers)
for phase 1, which increases to 86.0% for the phase II reading
paradigm. For the non–QIBA CTV-1 compliant lesions, the
percentage of observations in which the volume percent change falls
within ±30% is 71.7% (43 of 60 observations − 12 lesions × 5
reviewers) for phase 1, which increases to 91.7% for the phase 2
reading paradigm. Over the entire population of both compliant and
non-compliant lesions, the percentage of observations where the
volume percent change falls within ±30% is 79.4% (127 of 160
observations − 32 lesions × 5 reviewers) for phase 1, which increases to
88.1% for the phase 2 reading paradigm.
Figure 3 shows the Bland-Altman plots of volume percent change
for each reading paradigm for each individual reader. This figure
illustrates the differences between individual readers in each phase and
emphasizes that smaller lesions were most likely to have larger percent
differences. This figure also illustrates the differences between readers,
especially in the phase 1 independent reading paradigm, but there are
still instances of large differences in the phase 2 locked sequential
readings. Specifically, in phase 1, the mean (±2 * SD) percentage
changes are 36.5% (−269.3%, 342.3%), 32.1% (−174.7%,
238.9%), 17.9% (−151.7%, 187.5%), 6.2% (−89.6%, 102%),
and 24.4% (−199.6%, 248.4%) for reader 1, reader 2, reader 3,
reader 4, and reader 5, respectively. In phase 2, mean (±2 * SD fromBland-Altman plot (15)) percentage changes are 11.8% (−69.4%, 93%),
−2.8% (−36.4%, 30.8%), −1.4% (−49%, 46.2%), 27% (−130.6%,
184.6%), and 2.6% (−49.8%, 55%) for reader A, reader B, reader C,
reader D, and reader E, respectively.
Comparing the two phases, there is a trend toward a reduction in
the mean percent change in volume (P = .063). However, a similar
trend was not found for 1D and 2D (P = .99 and P = .11,
respectively). Nodule category (QIBA CVT-1 compliant or not) was
not statistically significant for any of the three sizing methods (P =
.22, P = .14, and P = .61, respectively).
Discussion
The purpose of this study was to determine the variability in lesion
size measurements for patients imaged on CT under a “no change”
condition. This is an important step in investigating the use of
changes in CT image–based estimates of tumor size as a biomarker of
response. If estimates of tumor size are to serve as more sensitive
indicators of change (and hence response to treatment) than current
methods, then the sources and magnitude of variation need to be
understood under conditions encountered in clinical practice. This
effort extends previous work by investigating the variation that exists
under a “no change” condition using two different reading paradigms,
three different sizing methods, five different readers, and 32 lesions
imaged by two scans performed within 15 minutes.
Our results indicate that the reading paradigm didmake a substantial
(but not statistically significant) difference in the measurement
variability. The locked sequential reading paradigm provided much
lower mean differences and much lower SDs than the independent
reading paradigm performed in phase 1 as shown in Figure 2. In fact,
Figure 2 shows that there is a trend toward improvement and the largest
improvement is in non–QIBA CTV-1 compliant lesions, where the
interquartile range decreased by half. Though the improvement in
QIBA compliant lesions is not large, the locked sequential read performs
no worse than the independent reading paradigm.
62 Variability of Lesion Size Measurements in CT McNitt-Gray et al. Translational Oncology Vol. 8, No. 1, 2015In the locked sequential reading paradigm, radiologists annotate the
lesion imaged at one time point, and when they are finished, then that
annotation is “locked” (no further editing allowed) and then the second
time point is displayed and annotated. The radiologist is allowed to
consult the annotation performed on the first time point. As one might
expect, this leads to much more consistent annotation of lesion
boundaries. Therefore, one of our strongest recommendations is to
perform the locked sequential reading paradigm wherever possible.
Readers were shown to be a source of variability based on the limit
of agreements from Bland-Altman plot within each phase. Figure 3
demonstrates that even within a reading paradigm, there are
noticeable differences in measurement variability between readers.
This is especially true for the independent reading paradigm. Perhaps
the largest improvement is due to the locked sequential reading
paradigm that allowed readers to be more consistent with their own
annotations by allowing them to refer to their previous markings as
they annotate the subsequent time point scan. This is most likely the
cause of the reduced variability when using the locked sequential
reading paradigm.
The change metric can also make a substantial difference. Two
metrics were described—percent change and proportional change
[in equations (1) and (2) in the Analysis section]. The proportional
change has been suggested as a metric that is less biased by lesion size
and has been recommended for use by the QIBA Metrology Working
Group [17,18]. The results from the current work demonstrate that
the proportional change consistently provides a lower mean value of
change as well as lower SDs. One example to illustrate these sources of
variability is described in Appendix A.
This work shows that variability within a sizing method may
be influenced by the reading paradigm. For example, the 1D
sizing method results do not change significantly or substantially
across reading paradigms (of note, the means were 2.75% with 95%
CI [−2.34%, 7.83%] in the independent reading and 2.52% with
95% CI [−0.28%, 5.33%] in the locked sequential reading). However,
volume measurements do change substantially and differences are
lower for the locked sequential reading paradigm, but this did not reach
statistical significance (P = .067; of note, the summary statistic, the
means were 23.40% with 95% CI [−2.36%, 52.34%] in the
independent reading and 7.42% with 95% CI [−0.98%, 15.82%]
in the locked sequential reading). This may be due to the number of
choices each radiologist has to make when contouring the boundary of
an entire lesion (i.e., the reader has to define every voxel to include as
part of the lesion) and the consistency of those choices when being able
to refer to a previously generated contour. When making a single linear
measurement, there are fewer choices to make on an individual lesion
(i.e., the reader has to only define the slice and the endpoints of the
longest dimension) and so variability may not be as affected by the
different reading paradigms.
The results of this work do show higher percent change values,
even for the locked sequential reading paradigm, for the 3D
(volumetric) measurements than for the 1D (linear) measurements
across all lesions: 7.4% for mean percent change in 3D compared to
2.5% mean percent change in 1D; 2.2% for mean proportional
change in 3D compared to 1.7% mean proportional change for 1D.
However, Petrick [6] suggested normalizing percent size change
metrics to a common scale to allow comparisons. This is
accomplished by converting 2D and 3D size estimates to a 1D
(mm) scale by taking the square root and cube root, respectively, of
the size estimates. While in this manuscript we reported the raw(unnormalized by size) percent and proportional differences in the
tables, the normalized 3D (volumetric) values would be 2.4% for
mean percent change and 0.7% for the mean proportional change,
which are quite comparable to the 1D (linear) values. Therefore, our
conclusion is similar to that of Petrick, which is that 3D and 1D can
both provide small measurement variability and especially so when
the locked sequential read is used. Unlike Petrick’s work, this work is
unable to assess bias as the true lesion size is not known.
Finally, this work did not show much difference in measurement
variability across different lesion categories (QIBA CTV-1 profile
compliant or non-compliant; P = .363). That profile limited its
claims to those lesions where “tumor margins are sufficiently
conspicuous and geometrically simple enough to be recognized on
all images.” The results in Tables 3 to 6 demonstrated no significant
differences in mean percent change, SD of percent change, mean
proportional change, or SD of proportional change across lesion
category for any of the sizing methods or for either reading paradigm.
Results from Figure 2 indicate that there are both QIBA compliant
and non-compliant lesions that can result in outliers that produce
significant variation in size (N200% difference in volume). However,
this figure indicates that for the independent reading paradigm
performed in phase 1, the IQR for the QIBA non-compliant lesions
exceeds the ±30% claim of the QIBA CTV-1 profile. It also shows
that for the locked, sequential reading paradigm there is small change
in the mean percent differences but some improvement in the outliers
for both QIBA compliant and non-compliant lesions as well as
theIQR for the non-compliant lesions. Although the 95% CIs of
Tables 3 to 6 indicate that these differences are not statistically
significant, this is perhaps due to the small sample size of lesions
(20 in the QIBA CTV-1 compliant group and only 12 in the non-
compliant group). The overall mean differences between the two
phases were 16% (=23% − 7%) with 32 subjects and 5 readers
(Tables 3 and 5). These results do indicate a trend toward
improvement, both in reducing variance and in reducing the number
and range of the outliers, when the locked sequential read is used,
especially for non-compliant lesions. The result that only a trend (i.e.,
differences did not reach statistical significance) was found between
the two reading paradigms can be due to several factors, including
performance of the experienced radiologists, whose markings of
volume segmentations reached large variations in only a few cases in
the independent reading. A simulation study was performed, which
indicated that a sample size of 41 subjects was required to achieve
approximately 80% power to detect a difference of 16% in volume
between the two phases at the 5% significance level. This was based
on having a paired reading with a correlation of 0.5 and using a two-
sided paired t test based on 20000 Monte Carlo samples using the
mean and SD values from Tables 3 and 5 [19].
A limitation of our study is that we do not know clinical truth for
the individual tumors, only that the difference between scans should
be zero. Therefore, we cannot determine the accuracy for any of the
individual measurements. This limitation is not unique to our study
but is a limitation of any study that analyzes patient CT data.
However, analysis of the accuracy and precision, or their combina-
tion, is likely important to fully characterize the performance of a
quantitative imaging biomarker. It is also clear from our study that
the differences observed between scans of the same lesion are unlikely
to be solely associated with inconsistencies produced by the software
tool and reader. Instead, some lesions actually present differently in
the two CT scan data such that simply segmenting the lesions would
Table A1. Results for the Case Shown in Figure 1D Using Volume Measurements and Percent Change Calculations for Each Reader, Reported for Both the Independent Reading and Locked Sequential
Reading Phases.
Reading Paradigm Reader Volume 1 (mm3) Volume 2 (mm3) Percent Change (%) Proportional Change (%)
Phase 1—independent read 1 5,220 16,720 219 105
Phase 1—independent read 2 25,750 87,700 240 109
Phase 1—independent read 3 15,720 17,060 8.49 8.15
Phase 1—independent read 4 17,910 14,980 −16.4 −17.8
Phase 1—independent read 5 10,340 12,890 24.7 22.0
Phase 2—locked sequential read A 17,630 16,690 −5.31 −5.45
Phase 2—locked sequential read B 17,370 18,210 4.84 4.72
Phase 2—locked sequential read C 16,090 11,730 −27.1 −31.3
Phase 2—locked sequential read D 13,140 16,760 27.5 24.2
Phase 2—locked sequential read E 25,520 21,760 −14.7 −15.9
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variability likely defines a lower bound on achievable quantitative
performance for a particular acquisition protocol.
Although this study used the same CT image data that were used in
the study described by Zhao et al. [7], there were several important
differences between these two studies including the selection of
different lesions, different readers and numbers of readers (three in
Zhao et al. and five in this study), and a longer washout period
between readings for this study. It should also be noted that in this
study two different reading phases (independent and locked,
sequential reading) were used, while in the study of Zhao et al. a
sequential reading paradigm was used. These differences make direct
comparisons difficult; however, both studies have shown that
variation increases for smaller sized lesions, independent of the sizing
method used.
Quantitative imaging–based biomarkers involve more than just the
acquisition and interpretation of image data; they require consistent
application of protocols to reduce both bias and variance of a
measurement system. For a tumor size–based biomarker using CT
imaging, this means that these protocols must address many aspects
including patient preparation, image acquisition and reconstruction,
image analysis, interpretation paradigm, and even inclusion criteria
(size, complexity, and so on) for lesions to be measured. Each of these
factors contributes to the bias and variance of the measurement system;
therefore to use imaging biomarkers as a sensitive measure of treatment
response requires addressing each of these issues. In this work, we have
addressed some of the important and necessary issues in reading
paradigm, lesion size, and complexity, as well as measurement method in
making CT tumor size a viable imaging biomarker.
Acknowledgements
The authors acknowledge the efforts of several key contributors to
this work. CoreLab Partners, Inc conducted the reader study
component of this investigation. They provided the reading facility,
review workstations, software, and logistical support. CoreLab
Partners radiologists also participated as readers. Therefore, we
acknowledge CoreLab Partners for their support and specifically
acknowledge CoreLab Partners radiologists Kevin Byrne, Steven
Kaplan, Julie Barudin, Joyce Sherman, Kathy Slazak, George
Edeburn, and J. Michael O'Neal for participating as readers in this
study. Finally, we acknowledge financial support from the RSNA
Quantitative Imaging Biomarker Alliance (QIBA) provided by
National Institute of Biomedical Imaging and BIoengineering
American Recovery and Reinvestment Act of 2009 funds. Certain
commercial equipment, instruments, software, or materials are
identified in this paper to foster understanding. Such identificationdoes not imply recommendation or endorsement by the National
Institute of Standards and Technology nor does it imply that the
materials or equipment identified are necessarily the best available
for the purpose. Similarly, the mention of commercial entities, or
commercial products, their sources, or their use in connection with
materials reported herein is not to be construed as either an actual or
implied endorsement of such entities or products by the Depart-
ment of Health and Human Services or the United States Food and
Drug Administration.
Appendix A. A Sample Set of Results to Illustrate
Reader Variability
An example to illustrate the sources of variation is based on the
lesion displayed in Figure 1D. For this individual case, we have the
results for both reading paradigms and all five readers for volumetric
measurements shown in Table A1. This table demonstrates that even
within a single lesion there are differences across both reading
paradigm and readers. From this table, the averages of the absolute
values of percent change are 101.8% for the independent reading and
15.9% for the locked sequential read. This table also shows the range
of percent change values across readers: in the independent reading,
the percent changes for different readers ranged from −16.4% to
240%, while for the locked sequential read, the percent changes for
different readers ranged from −27.1% to 27.5%. As can be seen in
Figure 1D, this lesion is reasonably complex and was not judged to be
compliant with the QIBA CTV-1 profile, but in the locked sequential
reads, the percent differences werewithin 30%.These results demonstrate
the uncertainty of obtaining a consistent boundary for this lesion,
resulting in variation from reader to reader that extends across both
reading paradigms. Even under the locked sequential reading paradigm,
where the readers did have access to their contours from the first time
point scan, there is still uncertainty in the contours.
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